Table 3

Primary and secondary outcomes of patients

EndpointsMedical strategy
(n=38)
Interventional strategy
(n=34)
Absolute difference, % (95% CI)P value
30-day bleeding recurrence17 (44.7)4 (11.8)33.0 (13.8 to 52.1)0.002
90-day bleeding recurrence18 (47.4)5 (14.7)32.7 (12.8 to 52.5)0.003
In-hospital complications rate04 (11.8)11.8 (0.9 to 22.6)0.045
90-day rate of rehospitalisation or invasive treatment for bleeding recurrence, n (%)*9/35 (25.7)2/32 (6.3)19.5 (2.7 to 36.2)0.032
Length of hospital stay (days)4.0 (3.0–7.0)4.0 (3.0–9.0)0.75†
Mortality rate of 30 and 90 days‡00
  • Data are n (%) or median (IQR 25%–75%).

  • *Analysis restricted to patients followed up to day 90. Bleeding recurrence status was missing at day 90 for four patients; invasive treatment was missing for one patient with bleeding recurrence during hospitalisation.

  • †Wilcoxon test.

  • ‡Two patients in the medical strategy group were lost to follow-up at day 30 (at days 2 and 29, respectively); four other patients were lost to follow-up at day 90 (one patient in the medical strategy at day 74 and three patients in the interventional strategy at days 40, 48 and 67, respectively; see the online supplemental 2, e-Table 1). The mean/median duration of follow-up was 94.6±22.6 days/92 (90–99) days.